Published: June 22, 2022

PR Newswire

A study published in "Frontiers in Oncology" reveals that daily supplementation with the mushroom extract AHCC® significantly supports the immune system in clearing HPV infections in two-thirds of participants within six months. Conducted by UTHealth Houston and funded by the NIH, this Phase II trial demonstrated the potential of AHCC® in reducing the long-term risk of HPV-related cancers, offering a promising adjunct to current preventive measures. The study highlights AHCC®'s safety and efficacy, suggesting its consideration for managing persistent high-risk HPV infections.


Read Full Article Here